Cell Signaling Technology, Ventana Ink Deal for EGFR Detection Technology | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Cell Signaling Technology today announced it has licensed its patent rights and proprietary antibody reagents related to the detection of epidermal growth factor receptor mutations to Ventana Medical Systems.

The non-exclusive licensing agreement is for the field of tissue-based in vitro diagnostics testing, the Danvers, Mass.-based antibody firm said. Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.